Pharmacogenetics of antipsychotics: useful for the clinician?

  title={Pharmacogenetics of antipsychotics: useful for the clinician?},
  author={Brigitta Bondy and Ilja Spellmann},
  journal={Current Opinion in Psychiatry},
Purpose of review The concept of individualized drug therapy on the basis of pharmacogenetics has become a central focus in psychopharmacology of schizophrenia. This article reviews recent advances in this field with respect to their importance for the clinician. Recent findings First, there is an increasing agreement about the importance of polymorphisms in cytochrome P450 enzymes and the effects of drug–drug interactions in relation to the incidence of adverse effects. Secondly, prediction of… 

Pharmacogenetics and antipsychotics in the light of personalized pharmacotherapy.

This review summarizes the present knowledge of associations between cytochrome P450 isoenzymes and the efficacy and side effects of antipsychotics.

Should we be 'pushing meds'? The implications of pharmacogenomics.

The impact that pharmacogenomics and pharmacogenetics are having in the field of mental health has implications for the way in which practitioners consider medication adherence.

Pharmacogenetics and interactions of antidepressants in the treatment of co-morbid illness.

Clinicians can improve outcomes of depressed patients, by considering the possibility of drug interactions both before prescribing a specific antidepressant and while monitoring for response, adverse effects and patient compliance.

Iloperidone: A new drug for the treatment of schizophrenia.

  • Sally A. ArifMelissa Mitchell
  • Medicine, Psychology
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2011
Iloperidone may be a viable and safe option for the treatment of schizophrenia in adult patients, especially for patients who cannot tolerate other antipsychotic agents.

Molecular study of weight gain related to atypical antipsychotics: clinical implications of the CYP2D6 genotype.

The CYP2D6 genotype in children and adolescents with schizophrenia and bipolar disorder, proved to be a good predictor for the response to atypical antipsychotics and the side effects registered, proving the fact that the pharmacogenetic screening is needed in the future clinical practice, allowing for individualized, tailored treatment, especially for at-risk individuals.

Therapeutic Drug Monitoring of Common Antipsychotics

A straightforward relationship between administered dose, plasma or serum concentration, clinical outcome, or adverse effects is often lacking, so extensive research in this field is still mandatory.

New atypical antipsychotics for schizophrenia: iloperidone

In double-blind phase III trials iloperidone reduced the symptoms of schizophrenia at oral doses from 12 to 24 mg and was more effective than placebo in reducing positive and negative syndrome total score and Brief Psychiatric Rating scale scores; it was as effective as haloperidol and risperidone in post-hoc analysis.

Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample.

The results contribute to the accumulating evidence for an association of the X-chromosomal HTR2C gene with antipsychotic-induced BWG and the proposed underlying mechanisms include decreased HTR1C gene expression with reduced 5-HT-modulated activation of hypothalamic proopiomelanocortin-neurons, and inverse 5- HT(2C) agonism in the presence of D(2) receptor antagonism.

Genetic Polymorphism and Major Depression: New Theories

Developments in DNA sequencing make it relatively simple to look for allelic versions of a gene by examining samples of a specific gene taken from different members of a population, called polymorphisms.



The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment

The emerging role of pharmacogenetics: implications for clinical psychiatry.

Genotyping, especially for drug metabolizing enzymes, could enable more rational, cost-effective and optimal prescribing in future psychopharmacotherapy and must also be considered as cultural and environmental factors significantly impinge on response to medications.

Pharmacogenomics in schizophrenia: the quest for individualized therapy.

This review will provide demonstrative examples of functional candidate gene variants studied in a variety of antipsychotic response phenotypes in the treatment of schizophrenia, and the merits and weaknesses of neuroimaging technologies as applied to pharmacogenetic analyses are discussed.

Pharmacogenetics of antipsychoatics.

  • N. Ozaki
  • Psychology, Medicine
    Nagoya journal of medical science
  • 2004
The new field of pharmacogenomics using DNA microarray analysis, which focuses on the genetic determinants of drug response at the level of the entire human genome, is important for development and prescription of safer and more effective individually-tailored antipsychotics.

Pharmacogenomics: a path to predictive medicine for schizophrenia.

This review summarizes the available knowledge of associations between pharmacogenetics and drug response in schizophrenia and presents a network model of the interaction/crosstalk between the neurotransmitter signaling systems to emphasize the importance of the genes associated with the molecular mechanisms of the disease and drugresponse.

Pharmacogenetics of antipsychotic-induced weight gain

Pharmacogenetic studies can provide powerful tools for the pre-treatment identification of individuals at high risk for antipsychotic-induced weight gain, to uncover biological mechanisms that may even generalize to non-drug-inducedWeight gain, and to isolate novel targets for treatments of weight gain and obesity.

Pharmacogenetics of schizophrenia

With improvements in defining the response phenotype in carefully assessed and homogeneous subject groups, the near future is likely to see the identification of genetic predictors of outcome that may inform the choice of pharmacotherapy.

Pharmacogenetics of Drug Metabolising Enzymes: Importance for Personalised Medicine

  • M. Oscarson
  • Biology, Medicine
    Clinical chemistry and laboratory medicine
  • 2003
In order to apply the increasing amount of pharmacogenetic knowledge to clinical practise, specific dosage recommendations based on genotypes will have to be developed to guide the clinician, and these recommendations will haveTo be evaluated in prospective clinical studies.

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

Combinations of polymorphisms in pharmacokinetic and pharmacodynamic pathways of relevance might contribute to identify genotypes associated with best and worst responders and they may also identify susceptibility to adverse drug reactions.

The Influence of Cytochrome P450 Pharmacogenetics on Disposition of Common Antidepressant and Antipsychotic Medications

Although CYP genotyping has been shown to predict the majority of aberrant phenotypes, it is currently rarely performed in clinical practice and may be an important reason for drug therapy failure.